{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,28]],"date-time":"2026-03-28T06:40:56Z","timestamp":1774680056392,"version":"3.50.1"},"reference-count":32,"publisher":"Public Library of Science (PLoS)","issue":"11","license":[{"start":{"date-parts":[[2022,11,3]],"date-time":"2022-11-03T00:00:00Z","timestamp":1667433600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Alcon Vision LLC, Fort Worth, Texas, USA"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:sec id=\"sec001\">\n<jats:title>Purpose<\/jats:title>\n<jats:p>To conduct a cost-benefit analysis of AcrySof IQ PanOptix trifocal intraocular lens (TFNT00 IOL) versus AcrySof monofocal IOL (SN60AT) from the patient perspective in the United States (US).<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec002\">\n<jats:title>Methods<\/jats:title>\n<jats:p>A de novo Markov model was developed to estimate the mean total lifetime patient costs and vision-related quality of life (measured as quality adjusted life-years (QALYs)) with each intervention (TFNT00 and SN60AT) and the incremental differences between these two treatments. The resulting incremental quality of life gain was mapped to the US patient willingness to pay threshold of $50,000 per QALY gain to estimate the lifetime net monetary value, measured as the net monetary benefit of TFNT00 IOL. Model inputs (transition probabilities, costs, discount rate, utilities, and event rates) were derived from the FDA IDE study (NCT03280108), published literature, clinical experience, and other relevant sources.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec003\">\n<jats:title>Results<\/jats:title>\n<jats:p>Bilateral cataract surgery with implantation of the advanced technology IOL (AT-IOL) TFNT00 provides improved vision-related quality of life (QALY gain of 0.67) at an incremental lifetime cost of $2,783 compared to monofocal IOL. This incremental QALY gain translated into a lifetime net monetary benefit of $30,941 at the patient willingness to pay threshold of $50,000\/QALY gain. Results were most sensitive to disutility due to wearing glasses, patient out of pocket costs for bilateral AT-IOL procedure, and post-operative spectacle dependence rates.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec004\">\n<jats:title>Conclusions<\/jats:title>\n<jats:p>AcrySof IQ PanOptix IOL provides greater improvement in vision related quality of life compared to no presbyopia correction with a monofocal IOL. This study shows PanOptix is a cost-beneficial treatment strategy for patients willing to pay out of pocket for cataract surgery.<\/jats:p>\n<\/jats:sec>","DOI":"10.1371\/journal.pone.0277093","type":"journal-article","created":{"date-parts":[[2022,11,3]],"date-time":"2022-11-03T17:44:13Z","timestamp":1667497453000},"page":"e0277093","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":15,"title":["Cost-benefit analysis of a trifocal intraocular lens versus a monofocal intraocular lens from the patient\u2019s perspective in the United States"],"prefix":"10.1371","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5468-7405","authenticated-orcid":true,"given":"John","family":"Berdahl","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chandra","family":"Bala","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mukesh","family":"Dhariwal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hemant","family":"Rathi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6012-238X","authenticated-orcid":true,"given":"Ritu","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2022,11,3]]},"reference":[{"key":"pone.0277093.ref001","doi-asserted-by":"crossref","first-page":"5872","DOI":"10.1167\/iovs.16-19894","article-title":"Cataract Surgical Rate and Socioeconomics: A Global Study","volume":"57","author":"W Wang","year":"2016","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"pone.0277093.ref002","first-page":"58","article-title":"The Evolution of Cataract Surgery","volume":"113","author":"G. Davis","year":"2016","journal-title":"Mo Med"},{"key":"pone.0277093.ref003","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1016\/j.clinthera.2014.07.009","article-title":"Cost-effectiveness comparison between monofocal and multifocal intraocular lens implantation for cataract patients in Taiwan","volume":"36","author":"JC Lin","year":"2014","journal-title":"Clinical Therapeutics"},{"key":"pone.0277093.ref004","doi-asserted-by":"crossref","first-page":"2310","DOI":"10.1016\/S0161-6420(03)00796-6","article-title":"Cost-utility analysis of cataract surgery in the second eye","volume":"110","author":"BG Busbee","year":"2003","journal-title":"Ophthalmology"},{"key":"pone.0277093.ref005","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1016\/j.ophtha.2006.12.013","article-title":"Global cost-effectiveness of cataract surgery","volume":"114","author":"VC Lansingh","year":"2007","journal-title":"Ophthalmology"},{"key":"pone.0277093.ref006","doi-asserted-by":"crossref","first-page":"3439","DOI":"10.2147\/OPTH.S269597","article-title":"Patient and Economic Burden of Presbyopia: A Systematic Literature Review","volume":"14","author":"J Berdahl","year":"2020","journal-title":"Clin Ophthalmol"},{"key":"pone.0277093.ref007","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1186\/s12886-019-1204-0","article-title":"Efficacy and safety of extended depth of focus intraocular lenses in cataract surgery: a systematic review and meta-analysis","volume":"19","author":"J Liu","year":"2019","journal-title":"BMC Ophthalmol"},{"key":"pone.0277093.ref008","volume":"13","author":"CMS Rulings","year":"2021","journal-title":"Accessed August"},{"key":"pone.0277093.ref009","article-title":"Alcon Laboratories, Inc","author":"U.S. Food and Drug Administration","year":"2019","journal-title":"AcrySof\u00ae IQ PanOptix\u00ae Trifocal Intraocular Lens (Model TFNT00) and AcrySof\u00ae IQ PanOptix\u00ae Toric Trifocal Intraocular Lens (Models TFNT30, TFNT40, TFNT50, TFNT60)"},{"key":"pone.0277093.ref010","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.ophtha.2020.07.015","article-title":"Visual and Patient-Reported Outcomes of a Diffractive Trifocal Intraocular Lens Compared with Those of a Monofocal Intraocular Lens","volume":"128","author":"S Modi","year":"2021","journal-title":"Ophthalmology"},{"key":"pone.0277093.ref011","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.ajo.2019.03.019","article-title":"Cost-Effectiveness Analysis of Multifocal Intraocular Lenses Compared to Monofocal Intraocular Lenses in Cataract Surgery","volume":"208","author":"JQ Hu","year":"2019","journal-title":"Am J Ophthalmol"},{"issue":"11","key":"pone.0277093.ref012","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1016\/j.jcrs.2008.07.024","article-title":"A United States cost\u2013benefit comparison of an apodized, diffractive, presbyopia-correcting, multifocal intraocular lens and a conventional monofocal lens","volume":"34","author":"WA Maxwell","year":"2008","journal-title":"Journal of Cataract & Refractive Surgery"},{"key":"pone.0277093.ref013","unstructured":"Alcon (2018) Data on File. Clinical Study Report TDOC\u20140055352."},{"issue":"8","key":"pone.0277093.ref014","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1016\/j.jcrs.2016.07.017","article-title":"LASIK outcomes: How are we doing and can we do better","volume":"42","author":"WJ Dupps","year":"2016","journal-title":"Journal of Cataract and Refractive Surgery"},{"key":"pone.0277093.ref015","article-title":"Directions for Use: AcrySof\u00ae IQ PanOptix\u00ae Trifocal IOL (Model TFNT00)","author":"Alcon Research Ltd","year":"2019","journal-title":"AcrySof\u00ae IQ PanOptix\u00ae Toric Trifocal IOL (Models TFNT30, TFNT40, TFNT50, TFNT60)"},{"key":"pone.0277093.ref016","author":"CDC","year":"2017","journal-title":"National Center for Health Statistics, Life tables"},{"key":"pone.0277093.ref017","article-title":"Trends in enrollment and demographics","author":"State of Medigap 2019","year":"2021"},{"key":"pone.0277093.ref018","unstructured":"Medicare. What does Medicare cost? Accessed May 4, 2021. https:\/\/www.medicare.gov\/basics\/get-started-with-medicare\/medicare-basics\/what-does-medicare-cost."},{"key":"pone.0277093.ref019","unstructured":"All About Vision. Multifocal intraocular lenses: multifocal IOL costs. Accessed May 10, 2021. https:\/\/www.allaboutvision.com\/conditions\/multifocal-iols.htm."},{"key":"pone.0277093.ref020","unstructured":"Alcon (2020) Data on File. Optical Industry value map."},{"key":"pone.0277093.ref021","unstructured":"Walmart.com. Accessed September 8, 2020. https:\/\/www.walmart.com\/."},{"key":"pone.0277093.ref022","unstructured":"NVISION. How frequently do you really have to change your glasses? Accessed May 10, 2021. https:\/\/www.nvisioncenters.com\/glasses\/change-how-often\/."},{"key":"pone.0277093.ref023","unstructured":"Drugs.com. Accessed September 8, 2020. https:\/\/www.drugs.com\/."},{"key":"pone.0277093.ref024","unstructured":"2020 ASC National Payment Rates: https:\/\/www.cms.gov\/files\/zip\/january-2020-asc-approved-hcpcs-code-and-payment-rates.zip."},{"key":"pone.0277093.ref025","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1001\/archophthalmol.2008.608","article-title":"Value-based medicine, comparative effectiveness, and cost-effectiveness analysis of topical cyclosporine for the treatment of dry eye syndrome","volume":"127","author":"MM Brown","year":"2009","journal-title":"Arch Ophthalmol"},{"key":"pone.0277093.ref026","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1023\/B:QURE.0000018475.17665.6e","article-title":"Testing subject comprehension of utility questionnaires","volume":"13","author":"DG Dobrez","year":"2004","journal-title":"Qual Life Res"},{"issue":"4","key":"pone.0277093.ref027","first-page":"688","article-title":"Changing indications for and improving outcomes of intraocular lens exchange","volume":"140","author":"GJ Jin","year":"2005","journal-title":"American journal of ophthalmology"},{"key":"pone.0277093.ref028","unstructured":"ICER 2020\u20132023 Value Assessment Framework. Accessed May 10, 2021. https:\/\/icer.org\/wp-content\/uploads\/2021\/03\/ICER_2020_2023_VAF_013120-4-2.pdf."},{"key":"pone.0277093.ref029","unstructured":"ICER\u2019s Reference Case for Economic Evaluations: Principles and Rationale. Accessed May 4, 2021. https:\/\/icer.org\/wp-content\/uploads\/2020\/10\/ICER_Reference_Case_013120.pdf."},{"issue":"4","key":"pone.0277093.ref030","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1097\/MLR.0b013e31815c31a7","article-title":"What does the value of modern medicine say about the $50,000 per quality-adjusted life-year decision rule?","volume":"46","author":"RS Braithwaite","year":"2008","journal-title":"Med Care"},{"key":"pone.0277093.ref031","article-title":"Clinical Investigation of AcrySof\u00ae IQ PanOptix\u2122 IOL Model TFNT00. 2019","volume":"8","author":"Alcon Research","year":"2021","journal-title":"Accessed"},{"key":"pone.0277093.ref032","first-page":"2367","article-title":"Cataract surgery cost utility revisited in 2012: a new economic paradigm","volume":"120","author":"GC Brown","year":"2013","journal-title":"Ophthalmology"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0277093","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,3]],"date-time":"2022-11-03T17:44:44Z","timestamp":1667497484000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0277093"}},"subtitle":[],"editor":[{"given":"Guangming","family":"Jin","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2022,11,3]]},"references-count":32,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2022,11,3]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0277093","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,3]]}}}